Human Papillomavirus in Young People Epidemiological Research 3

Phase

N/A

Condition

Rectal Cancer

Rectal Disorders

Anal Dysplasia

Treatment

N/A

Clinical Study ID

NCT05587725

14/22

Ages 16-20
Male
Accepts Healthy Volunteers

Study Summary

Anal cancer is overrepresented among gay, bisexual and other men who have sex with men (MSM), particularly those living with HIV. Australia was the first country to introduce a publicly funded national HPV vaccination program in 2007. This program was expanded to include schoolboys aged 12-13 years in 2013; with a 2-year catch-up for boys aged up to 15 years. In 2018, the 9-valent vaccine (covering genotypes 6/11/16/18/31/33/45/52/58) replaced the 4-valent vaccine in the national program.

The goal of the HYPER3 study is to determine the prevalence of anal, genital and oral HPV among 200 young gay and bisexual men aged 16-20 years who were eligible for the school-based 9-valent vaccination.

Participants will be required to complete a questionnaire and provide samples for HPV testing. No follow-up visits will be required.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Men aged 16 to 20 (i.e. men aged 16-18 years in 2023; men aged 16-19 years in 2024;and men aged 16-20 years in 2025 will be recruited. This is to ensure these men wouldhave been eligible for the 9-valent school-based HPV program)
Same-sex attracted
Residing in Australia since 2018

Exclusion

Exclusion Criteria:

Unable to complete all study requirements in English

Study Design

January 01, 2023

December 31, 2025

Connect with a study center

Melbourne Sexual Health Centre
Melbourne, Victoria 3053
Australia
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.